Skip to main content

Harrow and iOR Partners Expand National Product Supply Agreement

Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

“We are thrilled to be working alongside iOR Partners as they mobilize an increasing number of cataract surgeons to perform surgery in an office-based environment, offering more personalized care in a patient-friendly setting,” said Mark L. Baum, Chairman and CEO of Harrow. “iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality. Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission.”

“Harrow, through its ImprimisRx division, is the gold standard in supplying innovative compounded ophthalmic formulations that meet the highest federal manufacturing standards. Their commitment to quality, exceptional customer service, and the breadth of their portfolio are why we chose them as our partner,” said Tony Burns, Founder and Principal of iOR Partners. “These qualities support our confidence that we are delivering on our promise of personalized care that’s safe and comfortable for patients.”

Burns continued, “One excellent example of a product we find compelling is the MKO Melt®, which has allowed us to substantially reduce the use of opioids and needles during office-based surgical procedures. As we continue to grow and assist cataract surgeons with their vision of providing office‑based cataract surgery, we look forward to collaborating to further expand our services.”

About iOR Partners

iOR Partners, LLC is paving the way for the future of cataract surgery with innovative, office-based surgery suites. iOR surgical suites provide cataract surgeons the ability to offer more personalized care in a safe and comfortable surgical environment. The company’s turnkey solution includes assistance with space build-out, acquiring surgical equipment, staff training, insurance acquisition, accreditation, and compliance services. iOR Partners is the only company dedicated to ophthalmic office-based surgery and partners with practices nationwide. For more information, visit

About Harrow

Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies for the U.S. market that are accessible and affordable. For more information about Harrow, please visit the Investors section of the corporate website,

Harrow Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the continued impact of the COVID-19 pandemic and any future health epidemics on our financial condition, liquidity and results of operations; our ability to make commercially available our FDA-approved products and compounded formulations and technologies in a timely manner or at all; market acceptance of the Company’s products and challenges related to the marketing of the Company’s products; risks related to our pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our products; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and products; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10‑K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's website at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward‑looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

* Harrow’s compounded formulations are customized to meet unique patient and practitioner needs. No compounded medication is reviewed by the FDA for safety or efficacy. Harrow does not compound copies of commercially available products.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.